FROM PUBLIC EVENTS · 2026-11-15

Current stage

  1. Discovery · preclinical
  2. Early clinical · first deals
  3. Late clinical · capacity
  4. Commercial · sales
  1. Global approvals · expansion
  2. M&A · integration
  3. Pipeline reshaping

Global approvals · expansion Exports of its molecular diagnostic kits grew and it returned to profit in the second quarter.

  • Second-quarter exports up 96% year on year, with a return to operating profit. Source

Roles often seen at this stageRegulatory affairs · Sales & marketing · Research & development

Companies at the same stage and their people flow →

← Company library
Korea / Company briefSources checked 2026-11-15

GeneMatrix

A maker of molecular diagnostic kits for infectious diseases that returned to profit in the second quarter of 2026 as exports grew.

Neoplex

Marketed

Molecular-diagnostics brand that led the company's export growth in 2026.

Completion reported

Reported a second-quarter operating profit as exports expanded.

Official role guide

GeneMatrix careers

Current availability unconfirmed

Observed 2026-11-15

Work
Unconfirmed — The official careers page could not be confirmed.
Experience & requirements
Unconfirmed — The official careers page could not be confirmed.

Information from a role guide does not establish a current vacancy.

Sources & coverage 1

A brief based on selected official material, not an exhaustive product or vacancy list.

  1. 진매트릭스, 2분기 영업익 4억원·흑자 전환 ↗뉴스핌 · Published 2026-08-12 · Sources checked 2026-11-15 · Original unavailable